Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
The market for non-metastatic prostate cancer is projected to experience substantial expansion due to the rise in disease awareness, enhanced screening methods, and advancements in early-stage detection. The presence of a burgeoning therapy pipeline including Relugolix (ORGOVYX) by Myovant/Sumitomo is contributing to this growth. This sector shows promising potential for development, with a notable increase in patients benefiting from improved treatment options.